Discontinued — last reported Q3 '23
Centene Equity Method Investments decreased by 2.6% to $16.60B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.1%, from $18.27B to $16.60B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 5.8% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.47B | $13.56B | $14.04B | $14.13B | $13.67B | $14.05B | $14.68B | $15.83B | $16.11B | $15.23B | $16.29B | $16.50B | $16.87B | $17.69B | $17.43B | $18.27B | $18.80B | $18.18B | $17.04B | $16.60B |
| QoQ Change | — | +0.7% | +3.6% | +0.6% | -3.2% | +2.8% | +4.5% | +7.8% | +1.7% | -5.4% | +6.9% | +1.3% | +2.3% | +4.9% | -1.5% | +4.8% | +2.9% | -3.3% | -6.3% | -2.6% |
| YoY Change | — | — | — | — | +1.5% | +3.6% | +4.6% | +12.1% | +17.8% | +8.4% | +10.9% | +4.2% | +4.7% | +16.1% | +7.0% | +10.7% | +11.4% | +2.8% | -2.3% | -9.1% |